Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
MS
Big pharma activity expected once clinical trial data has been received
Why are II not interested, given covid news
Answer
We have been meeting with them, we have enough money, but we are talking to His, when time us right we will do it
Big institution investors will be invited 'when the time is right'
Next catalysts
Answer
Major milestones will be clinical data for Crohns, pass 2 data thus year and phase 2 MS data.
Apologies for spellings, I'm on my phone, listening and typing
Major catalyst in next few weeks
FFF thanks i understand what your saying, fat fingers and all x
Someone mentioned sidekick. Who was on call from TILS apart from Dr K?
Q. Is there a point in time to tweak Foramulab to something for first responders as an inhaler, a kind of bio shield.
A. Dr says its a great question. Something we are on top of
Q. Could Foramulab be fast tracked because of safety profile.
A. Need larger trial, which is uocoming
Q. Insider ownership
A. Answered by Keiren, no answer, check website
Felt like he couldn't say too much on the possibility of fast track!
Q. Design of MS and Crohns trial 2. And other covid competitors
A. Crohn in US and Europe. Us enrolment slow. So mire in Europe. Total patients 60. Data end 2021.
MS in US, with Harvard medical school. Weiner in charge. 45 patients. Documents with FDA, start hopefully very soon.
Covid. We are first and patented.
Q. Will our patent generate revenue.
A. Patent covers combinations and our anti body. Yes could be source of revenue
Q. Can covid be fast tracked?
A. Yes but need larger trial with severe patients
Chosen MS route due to interest from big pharma.....
Will be watching the recording again....
Q. Why share price dropping
A. I understand concerns and I'm frustrated, everything on track, no bad news, stock market beyond his control. I assure you no negative news
Q. Why should we invest in Tiziana
A. Look at the team, we have experience of concept to market drugs. If one of our drugs goes to market, its a game changer (my words, nit the goid Drs)
End of 2021 is going to be great, the end !!!!!
Thank you for all the information. Brilliant.
Start wasn't great, but really pleased with some if the responses to the questions...
I feel a lot better after that !
Thank you fullfathomfive!
Nice one FFF, much appreciated